Mankind Pharma’s Q3 FY25 revenue rises 24% to ₹3,230 crore, driven by a 30% growth in the OTC segment and 121% surge in exports. However, net profit dips 16% to ₹380.2 crore due to regulatory challenges, the company said in a press release on the stock exchanges.
The company’s EBITDA surged by 36.8% to ₹830 crore, reflecting a robust performance. The consumer healthcare business led with a 30% growth, while exports saw a remarkable 121% increase.
Mankind’s market share in India also grew, with chronic therapies and key OTC brands driving the company’s success. Despite the decline in net profit, the overall performance indicates a promising trajectory.
Mankind Pharma Ltd reported its Q3 FY25 results with a revenue of ₹3,230 crore, up 24% YoY, and a net profit of ₹380.2 crore, which declined by 16%.
In a recent business development Mankind Pharma announced the sale of its partnership interest in Mankind Specialties to Vascare Sciences Private Limited for approximately ₹4 crore.
The decision was approved by the company’s Board of Directors on December 3, 2024. Mankind Specialties, which generated a revenue of ₹2.60 crore (0.03% of Mankind Pharma’s total revenue) in FY 2023-2024, has a net worth of ₹3.26 crore.
The transaction, set to be completed by January 31, 2025, is not a related party transaction and is conducted at arm’s length.
Additionally, the company said that the sale does not involve any interest from the promoter group or its associates. The transaction is subject to due diligence and customary requirements before final execution.
Mankind Pharma’s share price traded 4.13% lower at ₹2,526.10 at 10:10 AM on the NSE, after opening at ₹2,560, down from ₹2,635.05 at the previous close. The stock had gained 4.67% in yesterday’s session, ending a two-day losing streak.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jan 24, 2025, 10:16 AM IST
Neha Dubey
Neha Dubey is a Content Analyst with 3 years of experience in financial journalism, having written for a leading newswire agency and multiple newspapers. At Angel One, she creates daily content on finance and the economy. Neha holds a degree in Economics and a Master’s in Journalism.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
